drugset
Drugs / IMNN-001
last change May 2026 re-read 2 minutes ago

IMNN-001

also known as GEN-1

Other / unclassified

Developed for
primary peritoneal carcinoma · fallopian tube cancer · malignant epithelial tumor of ovary · fallopian tube carcinoma · ovarian cancer · ovarian carcinoma · ovarian clear cell cystadenocarcinoma · ovarian endometrioid adenocarcinoma
+4 more · ovarian seromucinous carcinoma · ovarian serous cystadenocarcinoma · peritoneum cancer · undifferentiated ovarian carcinoma
Investigated by
Imunon · Gynecologic Oncology Group · National Cancer Institute (NCI) · Breakthrough Cancer Research

Trials 6 · a red edge is where a trial was stopped

today NCT06915025 · Ph 3 NCT05739981 · Ph 1/2 NCT03393884 · Ph 1/2 NCT02480374 · Ph 1 NCT01489371 · Ph 1 NCT01118052 · Ph 2
20112012201320142015201620172018201920202021202220232024202520262027202820292030203120322033
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT02480374 Sep 2015 → May 2017 fallopian tube cancer, malignant epithelial tumor of ovary, peritoneum cancer Imunon Completed No outcome recorded
Phase 1 NCT01489371 Jul 2012 → Dec 2014 fallopian tube carcinoma, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma +3 Gynecologic Oncology Group Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05739981 Feb 2023 → Jun 2027 expected fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma Imunon Recruiting No outcome recorded
Phase 1/2 NCT03393884 Sep 2018 → Jul 2024 overdue fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma Imunon Active not recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT01118052 Nov 2010 → Jul 2016 fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma Gynecologic Oncology Group Completed No outcome recorded
Phase 31 trial
Phase 3 NCT06915025 Jul 2025 → Oct 2032 expected fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma Imunon Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as IMNN-001 “Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer” NCT05739981 ↗
3

NCT06915025 ↗

NCT02480374 ↗

NCT03393884 ↗
Known as GEN-1 “Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer” NCT05739981 ↗
3

“Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)” NCT03393884 ↗

NCT01118052 ↗

NCT01489371 ↗
Modality Other / unclassified “PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1” NCT01489371 ↗
Route Other “intraperitoneal IMNN-001” NCT03393884 ↗